The efficacy and safety of a drug cannot be assessed unless it is being taken as instructed. This applies equally to the prescription of a drug to an individual patient and in the assessment of new drugs in clinical trials. The ways of determining the degree of compliance-the extent to which the patient adheres to instructions-can be divided into indirect and direct methods. ' Indirect methods of assessment include outcome, detection ofphysiological markers, the physician's impression, structured interviews, prescription filling, pill count, and medication monitors. The outcome of an effective regimen of treatment or prevention might seem at first sight to be a reasonable measure of compliance, and there are some reports of a relation between non-compliance and failure. For example, streptococcal infection can be shown to be a risk for non-compliant patients with rheumatic fever prescribed oral penicillin,2 and uncontrolled epilepsy is a risk for patients prescribed phenytoin.3 This method takes no account of the effects of other aspects of medical care not mediated by compliance.
Sometimes a physiological marker is available-for example, when the reduction in exercise-induced tachycardia produced by a beta-blocking drug can distinguish compliant and noncompliant patients. Many doctors believe that they can make that distinction on the basis of their clinical impression, but studies of compliance among patients with peptic ulcer and their consumption of antacids4 and of patients' return for follow-up and their adherence to treatment5 suggest that this confidence is unwarranted. A study of oral antibiotics given to children with rheumatic fever for prophylaxis against streptococcal infection6 suggested that a structured interview might be more successful in identifying non-compliant patients. Exam some fluid or tissue from the patient for the drug or a marker. This approach has several problems, including the sensitivity and specificity of the method of detection and the interpretation of the results. Sampling of blood has been used to detect carbon monoxide in smokers'4 and propranolol in hypertensive patients receiving dialysis.'5 The study of smokers showed that up to 40%0 of those who stated that they had reformed had not, while 53%0 of the patients prescribed propranolol were noncompliant. Urine sampling can be used to assess adherence to an antibiotic regimen.16 When it is impossible to detect either the medication or any metabolite directly, a detectable label may be added to the medication. The requirements of an effective label include non-toxicity, stability in urine, rapid noncumulative excretion, availability of a sensitive and specific detection method, and inability of the patient to detect it.9 Among markers which have been used are riboflavine, sodium bromide, phenol red, -and quinine. One problem with the measurement of drug, metabolite, or marker in blood or urine is the variation due to pharmacokinetic differences between patients, and differences in drug recovery may not be due solely to differences in compliance. Furthermore, the presence of the drug or marker indicates compliance only at the time of sampling and may mislead. By combining a marker with tablet counts9 compliance rates in a general practice among a group of patients with depression, acute infections, and in pregnancy were examined with confidence and without detracting from the doctor-patient relationship.
Some drugs can be recovered from faeces, and this method was used in a study of compliance with iron treatment in pregnant women, which showed that 32% of them were not taking their tablets.17 The detection of drugs in urine can be simplified when a specific stick test is available.'8 Breath testing has been used to detect carbon monoxide in a trial of the effect of nicotine chewing gum in abstinence from cigarettes in smokers'9 and to detect carbon disulphide,20 a metabolite of disulfiram, in alcoholics.
All these methods give a record of ingestion at the time of sampling, but recent ingenious advances may allow a more longitudinal survey to be performed, particularly of abstinence from alcohol and drugs of abuse. Several drugs are secreted into sweat in concentrations proportional to that in blood. Absorbent pads were used2' to collect sweat at a steady rate over eight days in a study to test for alcohol use over a period of time. Hair sampling22 can provide useful information on heroin and cocaine used over the preceding two years. The drugs are not easily removed by washing, and the time course of drug use can be reconstructed by testing hair segments at different distances from the root.
A possible unwanted effect of all methods of detecting noncompliance is the destruction ofthe doctor-patient relationship. In clinical practice, when treatment fails and non-compliance seems a possibility, questions should be asked in a way that does not imply criticism and allows the patient to answer truthfully without humiliation. Better to ask "Were you able to take the tablets ?" than "Did you take the tablets ?" In routine clinical practice the consequences of failing to detect non-compliance may be serious or bizarre. Those patients who take treatment consistently can then be entered in the study, and overall adherence to treatment again assessed-with tablet counts and blood or urine testing through the study proper.
No method of assessing compliance is completely effective. In particular, patients who take a single or a few doses immediately before assessment and discard the remainder are especially difficult to detect even when a combination of methods is used. All patients, whether from routine clinical practice or in studies, should be encouraged to bring back their medication at each visit. Though the corollary does not necessarily hold true, one single fact remains a beacon: if the tablets are in the bottle then they are not in the patient.
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